Skuteczność semaglutydu w leczeniu nadwagi i otyłości

Obesity. World Health Organization. https://www.who.int/health-topics/obesity#tab=tab_1. Accessed February 19, 2023.

Mean Bmi (kg/m²) (age-standardized estimate). World Health Organization. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/mean-bmi-(kg-m-)-(age-standardized-estimate). Accessed February 19, 2023.

Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21). doi:10.1161/cir.0000000000000973

Ge L, Sadeghirad B, Ball GDC, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ. Published online April 1, 2020:m696. doi:10.1136/bmj.m696

Patsalos O, Keeler J, Schmidt U, Penninx BWJH, Young AH, Himmerich H. Diet, Obesity, and Depression: A Systematic Review. JPM. 2021;11(3):176. doi:10.3390/jpm11030176

Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347(oct22 1):f5934-f5934. doi:10.1136/bmj.f5934

Idrees Z, Cancarevic I, Huang L. FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade. Cureus. Published online September 17, 2022. doi:10.7759/cureus.29262

Andrade Mesquita L, Fagundes Piccoli G, Richter da Natividade G, Frison Spiazzi B, Colpani V, Gerchman F. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis. Obesity Reviews. 2020;22(3). doi:10.1111/obr.13170

Commissioner Oof the. FDA approves new drug treatment for Chronic Weight Management, first since 2014. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chrema.onic-weight-management-first-2014. Accessed February 20, 2023.

Ema. Rybelsus. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus#product-information-section. Published July 26, 2022. Accessed February 20, 2023.

Dziennik Urzędowy - NIA.ORG.PL. https://www.nia.org.pl/wp-content/uploads/2022/12/lista-antywywozowa-28.12.2022.pdf. Accessed February 20, 2023.

Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726

Boer GA, Holst JJ. Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches. Biology. 2020;9(12):473. doi:10.3390/biology9120473

Wölnerhanssen BK, Cajacob L, Keller N, et al. Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects. American Journal of Physiology-Endocrinology and Metabolism. 2016;310(11):E1053-E1061. doi:10.1152/ajpendo.00037.2016

Dirksen C, Graff J, Fuglsang S, Rehfeld JF, Holst JJ, Madsen JL. Energy intake, gastrointestinal transit, and gut hormone release in response to oral triglycerides and fatty acids in men with and without severe obesity. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2019;316(3):G332-G337. doi:10.1152/ajpgi.00310.2018

Lee S, Yabe D, Nohtomi K, et al. Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes. Endocr J. 2010;57(2):119-126. doi:10.1507/endocrj.k09e-269

Smushkin G, Sathananthan A, Man CD, et al. Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes. The Journal of Clinical Endocrinology & Metabolism. 2012;97(2):589-598. doi:10.1210/jc.2011-2561

Young RL, Chia B, Isaacs NJ, et al. Disordered Control of Intestinal Sweet Taste Receptor Expression and Glucose Absorption in Type 2 Diabetes. Diabetes. 2013;62(10):3532-3541. doi:10.2337/db13-0581

Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. Diabetes Care. 2011;34(Supplement_2):S251-S257. doi:10.2337/dc11-s227

Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56(5):965-972. doi:10.1007/s00125-013-2841-0

Gribble FM, Meek CL, Reimann F. Targeted intestinal delivery of incretin secretagogues—towards new diabetes and obesity therapies. Peptides. 2018;100:68-74. doi:10.1016/j.peptides.2017.11.008

Tsuda T. Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon-like peptide-1 secretion. Mol Nutr Food Res. 2015;59(7):1264-1273. doi:10.1002/mnfr.201400871

Pyke C, Heller RS, Kirk RK, et al. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody. Endocrinology. 2014;155(4):1280-1290. doi:10.1210/en.2013-1934

Alavi SE, Ebrahimi Shahmabadi H. GLP-1 peptide analogs for targeting pancreatic beta cells. Drug Discovery Today. 2021;26(8):1936-1943. doi:10.1016/j.drudis.2021.03.032

Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism. 2022;57:101351. doi:10.1016/j.molmet.2021.101351

Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2017;20(3):610-619. doi:10.1111/dom.13120

Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. 2012;56(1):156-161. doi:10.1007/s00125-012-2738-3

Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932

Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Bækdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2020;23(2):581-588. doi:10.1111/dom.14255

Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal. 2020;229:61-69. doi:10.1016/j.ahj.2020.07.008

Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials. Diabetes & Metabolism. 2019;45(5):409-418. doi:10.1016/j.diabet.2018.12.001

Janić M, Rizzo M, Cosentino F, et al. Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Ther. 2022;13(4):795-810. doi:10.1007/s13300-022-01226-y

Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2021;70(1):5-13. doi:10.1136/jim-2021-001952

Ryan DH. Semaglutide for obesity: four STEPs forward, but more to come. The Lancet Diabetes & Endocrinology. 2021;9(5):252-254. doi:10.1016/s2213-8587(21)00081-4

Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials. Diabetes & Metabolism. 2019;45(5):409-418. doi:10.1016/j.diabet.2018.12.001

Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. doi:10.2337/dc19-0749

Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397(10278):971-984. doi:10.1016/s0140-6736(21)00213-0

Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2017;318(15):1460. doi:10.1001/jama.2017.14752

Meier JJ. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Front Endocrinol. 2021;12. doi:10.3389/fendo.2021.645617

Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2019;19(4):277-289. doi:10.1038/s41573-019-0053-0

Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA. Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clinical Therapeutics. 2016;38(7):1653-1664.e1. doi:10.1016/j.clinthera.2016.05.009

Nauck MA, Quast DR. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front Endocrinol. 2021;12. doi:10.3389/fendo.2021.645566

Anam M, Maharjan S, Amjad Z, et al. Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). Cureus. Published online December 16, 2022. doi:10.7759/cureus.32610

Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021;325(14):1403. doi:10.1001/jama.2021.1831

Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414. doi:10.1001/jama.2021.3224

Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4

Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022;10(3):193-206. doi:10.1016/s2213-8587(22)00008-0

Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022;327(2):138. doi:10.1001/jama.2021.23619

Alabduljabbar K, Al-Najim W, le Roux CW. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients. 2022;14(11):2217. doi:10.3390/nu14112217

Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725

Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414. doi:10.1001/jama.2021.3224

Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10. doi:10.3389/fpubh.2022.996179

Egan AG, Blind E, Dunder K, et al. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. N Engl J Med. 2014;370(9):794-797. doi:10.1056/nejmp1314078

Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12. doi:10.3389/fendo.2021.645563

Trujillo J. Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020;45(S1):43-60. doi:10.1111/jcpt.13225

Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic retinopathy—current perspective. Eye. 2021;36(1):10-11. doi:10.1038/s41433-021-01741-5

Mosterd CM, Bjornstad P, van Raalte DH. Nephroprotective effects of GLP-1 receptor agonists: where do we stand? J Nephrol. 2020;33(5):965-975. doi:10.1007/s40620-020-00738-9

Leiter LA, Bain SC, Bhatt DL, et al. The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(9):1690-1695. doi:10.1111/dom.14079

Lazzaroni E, Ben Nasr M, Loretelli C, et al. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological Research. 2021;171:105782. doi:10.1016/j.phrs.2021.105782

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/nejmoa2107519